Roche Says New MS Drug Works Better Than Merck & Co.'s Rebif
Roche said on Wednesday its Ocrevus multiple sclerosis drug controlled the most common form of the disease better than a rival's medicine and worked against another form of MS for which there is no approved treatment.
A 75 percent higher proportion of relapsing-remitting multiple sclerosis patients reached "no evidence of disease activity" status with Ocrevus in a head-to-head trial against Merck's Rebif, Roche said in a statement.
A 75 percent higher proportion of relapsing-remitting multiple sclerosis patients reached "no evidence of disease activity" status with Ocrevus in a head-to-head trial against Merck's Rebif, Roche said in a statement.